πŸ‡ΊπŸ‡Έ FDA
Patent

US 10301317

Inhibitors of ERK and methods of use

granted A61KA61K31/4439A61K31/4745

Quick answer

US patent 10301317 (Inhibitors of ERK and methods of use) held by Kura Oncology, Inc. expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kura Oncology, Inc.
Grant date
Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K31/4439, A61K31/4745, A61K31/513, A61K31/5377